AEterna Zentaris Inc. (USA)


Jim Simons’ Take on 3 Small Cap Biotech Stocks: Kamada Ltd, AEterna Zentaris Inc. (USA), Antares Pharma Inc

Known by many as “the world’s smartest billionaire”, Jim Simons is the founder of the prestigious Renaissance Technologies fund. The fund- one of …

AEterna Zentaris Inc. (USA) (AEZS) Engages Advisors and Provides Update to Shareholders

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that the special committee of independent directors (the “Strategic Review Committee”) has engaged a consulting firm …

AEterna Zentaris Inc. (USA) (AEZS) to Take Legal Action Against Former CEO and Former General Counsel

 AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced today that it has filed a claim against the Company’s former CEO David Dodd and its former General …

AEterna Zentaris Inc. (USA) (AEZS) CEO’s Departure Raises Questions

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are tumbling nearly 7% in Monday’s trading session, following the news that CEO David Dodd is stepping …

Maxim Hikes Price Targets on 2 Biotech Stocks: AEterna Zentaris Inc. (USA) (AEZS), Vertex Pharmaceuticals Incorporated (VRTX)

Many investors hope to win big on biotech stocks as shares can skyrocket when there is good news. Maxim analysts explain why there …

AEterna Zentaris Inc. (USA) (AEZS) Resubmits New Drug Application for Macrilen; Shares Rise

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are up nearly 8% in pre-market trading Friday, after the drug maker announced that it has resubmitted …

Analysts Shine Light on Merrimack Pharmaceuticals Inc (MACK) and AEterna Zentaris Inc. (USA) (AEZS)

Merrimack Pharmaceuticals In a research report sent to investors Wednesday, Cowen’s top analyst Eric Schmidt reiterated a Market Perform rating on shares of Merrimack …

Aeterna Zentaris Inc (USA) (AEZS) Announces Q1:17 Results

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) reported financial and operating results for the first quarter ended March 31, 2017.

Maxim Slashes Price Target on AEterna Zentaris Inc. (USA) (AEZS) Following Disappointing Clinical Results in Endometrial Cancer

AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) shares are collapsing 60% after underwhelming investors who had been optimistic about the company’s ZoptEC Phase 3 clinical study.